OCA
SLN

Octagon Capital Advisors’s Silence Therapeutics SLN Stock Holding History

Octagon Capital Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-176,000
Closed -$3.34M – 50
2024
Q2 		$3.34M Sell
176,000
-139,000
-44% -$2.96M 0.53% 34
2024
Q1 		$6.8M Buy
+315,000
New +$6.85M 0.82% 34

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Octagon Capital Advisors's SLN Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Silence Therapeutics (SLN) in Q3 2024, closing a stake of 176,000 shares — an estimated $3.34M sold.

Octagon Capital Advisors first reported a position in SLN in Q1 2024 and held it in 2 quarters. The position peaked at $6.8M in Q1 2024. 69 funds tracked by Wall St. Rank hold SLN as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Silence Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 176,000 Silence Therapeutics shares in Q3 2024, an estimated $3.34M.
  • Octagon Capital Advisors first reported a position in Silence Therapeutics in Q1 2024 and held it in 2 quarters.
  • Octagon Capital Advisors's Silence Therapeutics position peaked at $6.8M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.